Gainers & Losers Of The Day: ZSAN, EVOK, ARDX, EARS, NEOT...

Ardelyx Inc.'s phase III trial of Tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis has met its primary endpoint.

from RTT - Biotech http://ift.tt/2lN1dOt
via IFTTT